Home›Stock Screener›Adline Chem Lab

Adline Chem Lab Share Price Today | Stock Price & Adline Chem Lab Share Screener

ADLINE Pharmaceuticals

Track the current Adline Chem Lab share price and stock price live with TickJournal's free stock screener. Track ADLINE company valuation to gauge the company's total market size. Use the Adline Chem Lab stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Adline Chem Lab opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Adline Chem Lab Market Cap ₹5.14 Cr.
ADLINE P/E Ratio (TTM) -
Adline Chem Lab P/B Ratio -3.03
EPS (TTM) ₹-0.21
Dividend Yield -
Debt to Equity -
ADLINE 52 Week High -
Adline Chem Lab 52 Week Low -
Operating Margin -
Profit Margin -
ADLINE Revenue (TTM) -
EBITDA -
Net Income -
Total Assets -
Total Equity ₹-2.00

Adline Chem Lab Share Price Chart

Track the current stock price of Adline Chem Lab with an interactive chart. Analyse ADLINE share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Adline Chem Lab stock quote in one place.

Adline Chem Lab Company Profile - Fundamental Screener

Screen Adline Chem Lab company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ADLINE shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE276T01018.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E

Identifiers and Leadership

ISIN INE276T01018

Adline Chem Lab Balance Sheet Screener

Screen ADLINE balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2025, total assets were ₹0.

Item 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016

Assets

Total Assets 0 0 0 5 6 8 22 23 21 18
Current Assets 0 0 0 0 2 3 10 11 8 7
Fixed Assets 0 0 0 4 4 5 12 13 13 10

Liabilities

Total Liabilities 0 0 0 5 6 8 22 23 21 18
Current Liabilities 2 0 0 0 0 0 0 4 4 5
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity -2 -1 -2 3 2 3 7 7 7 7
Share Capital 6 6 6 6 6 6 6 6 6 6
Reserves & Surplus -7 -7 -7 -3 -4 -3 1 1 1 1

Adline Chem Lab Income Statement Screener - Profit & Revenue Analysis

Screen Adline Chem Lab income statement and profit fundamentals. Analyze ADLINE quarterly results. Adline Chem Lab reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For None-None, revenue was ₹0 and net profit was ₹0.

In that period expenses were ₹0, interest cost ₹0 and tax ₹0. The next period listed, 2025-March, shows revenue of ₹0 and net profit of ₹0.

Item None-None 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March 2015-March

Revenue and Expenses

Revenue 0 0 0 1 1 6 7 6 8 17 17 15
Expenses 0 0 0 1 1 7 10 5 7 16 17 14

Operating Costs and Margins

EBITDA 0 0 0 0 0 0 -3 1 1 1 1 1
Operating Profit % 0.00% 0.00% 0.00% 0.00% -40.00% -4.00% -51.00% 11.00% 11.00% 7.00% 3.00% 6.00%
Depreciation 0 0 0 0 0 1 0 1 1 1 0 1
Interest 0 0 0 0 0 0 0 0 0 0 0 1

Profit and Earnings

Profit Before Tax 0 0 0 -4 1 -1 -4 0 0 0 0 0
Tax 0 0 0 0 0 0 0 0 0 0 0 0
Net Profit 0 0 0 -4 1 -1 -4 0 0 0 0 0
EPS 0.00 -0.21 -0.46 -7.24 1.23 -2.19 -6.45 0.05 0.00 0.01 0.02 0.04

Adline Chem Lab Cash Flow Screener - Liquidity Fundamentals

Screen ADLINE cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2025-March, operating activities generated ₹0.

Over the same period, investing activities provided ₹0 and financing activities provided ₹0.

Item 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March

Cash from Operations and Investing

Operating Activities 0 0 0 0 0 -11 -1 1 3 1
Investing Activities 0 0 0 0 0 11 0 0 -3 0

Financing and Net Cash

Financing Activities 0 0 0 0 0 0 0 1 1 -1
Net Cash Flow 0 0 0 0 0 0 -2 2 0 0

Adline Chem Lab Shareholding Pattern Screener

See Adline Chem Lab shareholding pattern with promoter, FII, and DII holdings. Check Adline Chem Lab promoter holding and ownership changes for ADLINE on TickJournal, and see how institutional stock price moves affect the market.

In 2025-Mar, promoters held 29.61%, foreign institutions 0.00%, domestic institutions 0.00% and the public 60.13%, spread across 18,514 shareholders.

The shareholder count was 18,514 in 2025-Mar, compared with 18,481 in 2025-Jun.

Item 2025-Mar 2025-Jun 2025-Sept 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar

Promoter Holding

Promoter Holding 29.61% 29.61% 29.61% 29.61% 29.61% 29.61% 29.61% 28.24%

Institutional Investors

FII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
DII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 60.13% 60.16% 60.16% 60.29% 60.30% 60.32% 60.15% 61.51%
Other Holding 10.26% 10.23% 10.23% 10.10% 10.09% 10.07% 10.24% 10.25%
Shareholder Count 18,514 18,481 18,481 18,595 18,583 18,536 18,509 18,670

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Adline Chem Lab. Adline Chem Lab dividend yield can be compared with peers and other stocks in the market.

No dividends declared by Adline Chem Lab.

Adline Chem Lab Stock Index Membership - Nifty & Sensex

See which indices include Adline Chem Lab stock. Check ADLINE index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Adline Chem Lab is not part of any tracked indices.
Only major market indices are tracked in our system.

Adline Chem Lab Market Events Screener - Corporate Actions

Get Adline Chem Lab corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Adline Chem Lab stock events that may affect ADLINE share price, along with derivatives, futures and options activity and sector gainers.

9 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 12, 2025, with a record date of November 12, 2025.

It is followed by Quarterly Result Announcement dated August 12, 2025 and Annual General Meeting dated July 22, 2025.

Announcement Date Record Date Event Type Information Price Impact
2025-11-12 2025-11-12 Quarterly Result Announcement NA -9.67%
2025-08-12 2025-08-12 Quarterly Result Announcement NA 10.23%
2025-07-22 2025-07-22 Annual General Meeting NA -1.67%
2025-05-09 2025-05-09 Quarterly Result Announcement NA 1.95%
2025-02-04 2025-02-04 Quarterly Result Announcement NA -5.76%
2025-01-16 2025-01-16 Extraordinary General Meeting NA 4.36%
2024-11-13 2024-11-13 Quarterly Result Announcement NA -3.92%
2024-09-27 2024-09-27 Annual General Meeting NA 11.05%
2021-09-30 2021-09-30 Change Of Name NA -

Adline Chem Lab Competitors Screener - Peer Stocks Comparison

Screen ADLINE competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 424,634 39.93 54,729 9.71% 10,980 49.55
Divis Laboratories 172,860 69.20 9,712 18.67% 2,191 56.33
Torrent Pharmaceuticals 129,151 60.10 11,539 6.99% 1,911 61.47
Cipla 122,205 22.55 28,410 7.12% 5,291 49.47
Dr Reddys Laboratories 107,114 18.60 33,741 16.73% 5,725 60.05
Lupin 97,120 22.34 22,910 13.74% 3,306 65.28
Zydus Life Science 92,392 18.40 23,511 18.55% 4,615 40.07
Mankind Pharma 90,241 50.59 12,744 20.90% 2,007 45.53
Aurobindo Pharma 71,119 20.79 32,346 9.43% 3,484 59.88
Alkem Laboratories 67,243 27.59 13,458 3.70% 2,216 49.80

Adline Chem Lab Company Announcements - News & Reports Screener

Screen ADLINE latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 26, 2025.

The next most recent announcements are dated November 14, 2025 and November 12, 2025.

Date Update Actions
2025-11-26 Intimation Of Receipt Of Approval For Reclassification Application Of Promoter Under Regulation 31A Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. -
2025-11-14 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2025-11-12 Announcement under Regulation 30 (LODR)-Resignation of Chairman and Managing Director -
2025-11-12 Announcement under Regulation 30 (LODR)-Resignation of Director -
2025-11-12 Unaudited Standalone Financial Results Of The Company For The Quarter And Half Year Ended On 30Th September 2025 -
2025-11-12 Board Meeting Outcome for Board Meeting Outcome For Unaudited Standalone Financial Results Of The Company For The Quarter And Half Year Ended On 30Th September 2025 -
2025-11-05 Board Meeting Intimation for Consideration And Approval Of The Unaudited Standalone Financial Results For The Quarter And Half Year Ended September 30 2025. -
2025-10-15 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2025-09-30 Closure of Trading Window -
2025-08-14 Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer -
2025-08-14 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2025-08-12 Unaudited Standalone Financial Results Of The Company For The Quarter Ended June 30 2025 -
2025-08-12 Board Meeting Outcome for Board Meeting Outcome For Outcome Of Board Meeting For Unaudited Standalone Financial Results Of The Company For The Quarter Ended June 30 2025 -
2025-08-05 Board Meeting Intimation for Consideration And Approval Of The Unaudited Standalone Financial Results For The Quarter Ended On 30Th June 2025. -
2025-07-23 Scrutinizer"S Report -
2025-07-22 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2025-07-15 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2025-06-28 Reg. 34 (1) Annual Report. -
2025-06-28 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2025-06-27 AGM OF THE COMPANY SCHEDULED TO BE HELD ON TUESDAY 22ND JULY 2025 AT 02:00 P.M. -

Frequently Asked Questions

How is the company valued right now?

The P/B ratio is -3.03. Market capitalisation stands at ₹5.14 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.

About This Data

Key statistics were last updated on November 19, 2026. This page covers 10 balance sheet periods, 12 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.